Introduction {#Sec1}
============

Chemotherapy-induced nausea and vomiting (CINV) are the major adverse effects of cancer chemotherapy associated with substantial reductions in health-related quality of life (QoL) \[[@CR1]--[@CR3]\]. In the absence of antiemetic prophylaxis, \> 90% of patients receiving highly emetogenic chemotherapy and 30--90% of patients receiving moderately emetogenic chemotherapy experience emesis. Some combination therapies using receptor antagonists (RAs), such as 5-hydroxytryptamine-3 receptor antagonists (5-HT~3~-RAs), have been found effective against CINV in patients, but the effect was greatest in the acute phase (≤ 24 h post chemotherapy) \[[@CR4]\]. Delayed-phase (\> 24--120 h post chemotherapy) CINV has been found to have a greater impact on QoL than CINV experienced only in the acute phase \[[@CR1], [@CR3]\]. Rolapitant (VARUBI^®^) is a potent (Ki 0.66 nmol/L), selective, and competitive substance P/neurokinin-1 (NK-1) receptor antagonist approved for use in the USA as an adjunct to other antiemetic agents to prevent delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy in adults \[[@CR5], [@CR6]\]. Approval of the oral formulation by the US Food and Drug Administration (FDA) in 2015 was based on data from three global, randomized, double-blind phase 3 trials, in which rolapitant was well tolerated and provided, in combination with a 5-HT~3~-RA and dexamethasone, superior protection over a 5-HT~3~-RA and dexamethasone alone against CINV during the delayed phase \[[@CR7], [@CR8]\].

Oral rolapitant is formulated as a tablet and is administered approximately 1--2 h prior to the start of chemotherapy \[[@CR6]\]. Following administration, rolapitant is highly bioavailable, attains rapid and extensive brain penetration, and is slowly cleared (plasma half-life \[*t*~1/2~\], 169--183 h) \[[@CR5], [@CR8], [@CR9]\]. Findings from a positron emission tomography study demonstrated that a single oral 180-mg rolapitant dose provided at least 90% NK-1 receptor occupancy in the cortex for up to 5 days \[[@CR10]\]. These attributes allow for administration of a single dose of rolapitant during 5 days at-risk period of each cycle of chemotherapy, which is highly suitable for an antiemetic drug used along with complex anticancer treatment regimens. Rolapitant undergoes extensive oxidative metabolism to yield a single major active metabolite SCH720881 (M19; C4-pyrrolidine-hydroxylated rolapitant), the formation and elimination of which are slow and predictable \[[@CR6]\].

Unlike other NK-1 receptor antagonists (aprepitant and netupitant), rolapitant does not induce or inhibit cytochrome P450 (CYP) 3A4; hence, no dosage adjustment for dexamethasone (a CYP3A4 substrate) is needed when co-administered with rolapitant in an antiemetic treatment regimen \[[@CR9], [@CR11], [@CR12]\]. Findings from in vitro liver microsomal studies suggested that rolapitant inhibited the activity of human CYP2D6 enzyme at high concentrations (IC~50~ \> 7 μM) and had minimal inhibitory effects on CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19. The metabolite M19 is not an inhibitor of these CYP enzymes. Patients receiving emetogenic cancer chemotherapy may receive multiple concomitant medications, and several may have narrow therapeutic indices. Given the role of the CYP pathway in the metabolism of numerous drug classes \[[@CR13]--[@CR15]\], it is important to identify and quantify any drug--drug interactions in vivo to reduce the risk of adverse events (AEs) associated with specific drug combinations that include rolapitant.

Here we demonstrate a multipart, clinical, drug--drug interaction study to evaluate the potential effects of rolapitant and M19 on the pharmacokinetics (PK) of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8). These drugs are the commonly used probe substrates for the specific CYP enzymes \[[@CR16]\]. Safety and tolerability of rolapitant in combination with the CYP probes were also evaluated.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Studies were approved by the appropriate institutional or national research ethics committee (Aspire Institutional Review Board, Santee, CA, USA; protocol number, PR-10-5001-C). The study was conducted at the Parexel Early Phase Clinical Unit (Baltimore, MD, USA) between November 2011 and November 2012 and performed in compliance with the ethical standards as laid down in the 1964 Declaration of Helsinki (including amendments in effect up to the time the study was conducted), Guidelines of the International Conference on Harmonization on Good Clinical Practice, requirements of the Health Insurance Portability and Accountability Act of 1996, privacy regulations, and all other applicable regulatory requirements. Written informed consent was obtained from all subjects before enrollment in the study.

A total of 86 healthy subjects (dextromethorphan, *n* = 26; tolbutamide and omeprazole, *n* = 20; efavirenz, n = 20; repaglinide, n = 20) were enrolled in these studies. Inclusion criteria were healthy, nonsmoking male and female subjects aged 18 to 45 years with a body mass index (BMI) between 18.5 and 29.9 kg/m^2^ and weight ≥ 50 kg at screening. All subjects were determined to be in general good health, based on medical history, a physical examination, and vital signs. Female subjects had to have a negative serum pregnancy test prior to visit 1 and agree to use a medically accepted method of birth control throughout the study and for at least 30 days after dosing. All subjects were required to refrain from caffeine consumption and discontinue intake of alcohol, other beverages, or foods known to interfere with CYP metabolic enzymes. None of the subjects received continuous medication or used nicotine products.

For inclusion in the dextromethorphan part of the study, subjects were required to be identified as dextromethorphan normal or intermediate metabolizers. For inclusion in all of the studies, subjects had to have normal laboratory test results for serum aminotransferase concentrations and negative results for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, urine drug screen, and serum alcohol screen at screening. At the screening visit, blood samples were collected and sent to LabCorp (Research Triangle Park, North Carolina) for CYP2D6 genotyping (dextromethorphan study) and CYP2C9/2C19 genotyping (tolbutamide and omeprazole study). Subjects known to have a relevant CYP genotype allele combination predicting the phenotype as a poor metabolizer were excluded in the dextromethorphan and tolbutamide plus omeprazole studies to obtain relatively homogenous and drug-sensitive populations for study and to minimize variability for PK analysis.

Study design {#Sec4}
------------

These were phase 1, open-label, drug--drug interaction studies. Subjects were admitted to the study center prior to the study and remained in-house until completion of assessments. Investigational drugs were administered to the subjects in the morning on day 1 with approximately 240 mL (8 fluid ounces) of room temperature water after the subjects had fasted overnight for a minimum of 10 h. Subjects remained in a semi-recumbent position for at least 4 h after dosing. Each study part consisted of three dosing and sample collection periods.

In the dextromethorphan study, subjects (*n* = 26) received a single oral dose of 30 mg dextromethorphan on days 1 and 14 and a single dose of 180 mg rolapitant (four 45 mg rolapitant capsules) plus 30 mg dextromethorphan on day 7 (Fig. [1](#Fig1){ref-type="fig"}). In the tolbutamide and omeprazole study, subjects (*n* = 20) received a single oral cocktail of 500 mg tolbutamide and 40 mg omeprazole on days 1 and 14 and a single dose of 180 mg rolapitant (4 × 45 mg rolapitant capsules) plus the drug cocktail on day 7. Blood samples for PK analysis of rolapitant were collected at pre-dose and at multiple time points up to 72 h post dose on days 1, 7, and 14.Fig. 1Drug--drug interaction study in cohorts of 20 to 26 healthy subjects of orally administered CYP probe substrates (part A 30 mg dextromethorphan; part B 500 mg tolbutamide plus 40 mg omeprazole; part C 600 mg efavirenz; part D 0.25 mg repaglinide) in the absence and presence of single oral dose 180 mg rolapitant free base. ROL rolapitant

In the efavirenz study, subjects (*n* = 20) received a single oral dose of 600 mg efavirenz on days 1 and 17 and a single dose of 180 mg rolapitant (four 45 mg rolapitant capsules) and 600 mg efavirenz on day 10. Blood samples for PK analysis of rolapitant were collected at pre-dose and at multiple time points up to 120 h post dose on days 1, 10, and 17.

In the repaglinide study, subjects (*n* = 20) received a single oral dose of 0.25 mg repaglinide on days 1 and 10 and a single dose of 180 mg rolapitant (four 45 mg rolapitant capsules) and 0.25 mg repaglinide on day 3. Blood samples for PK analysis of rolapitant were collected at pre-dose and at multiple time points up to 12 h post dose on days 1, 3, and 10.

### Determination of plasma drug concentrations {#Sec5}

Following collection into K~2~-EDTA tubes, blood samples were immediately placed on ice. Plasma was separated by centrifugation at 4 °C, transferred to appropriately labeled polypropylene specimen containers, and frozen at − 20 °C until analysis (XenoBiotic Laboratories, Plainsboro, NJ, USA). Plasma samples were analyzed using fully validated liquid chromatography coupled with tandem mass spectrometry detection (LC/MS/MS) method for determination of the concentrations of dextromethorphan, tolbutamide, omeprazole, efavirenz, repaglinide, and rolapitant in ESI positive ion mode (API-4000, Applied Biosystem, MA) except for tolbutamide, to which negative ion mode was applied. The LC columns were Luna 5 μ HILIC 200A (100 × 2.0 mm) for dextromethorphan; Luna PFP (2) 50 × 2.0 mm for tolbutamide, omeprazole, and efavirenz; Luna C8 (2) 5 μ 50 × 2.0 mm for repaglinide; and an ACE (Milford, MA) C18-AR column (2.1 × 50 mm, 3μm) for rolapitant. The multiple reaction monitoring (MRM) transitions were 272.2/147.0 for dextromethorphan, 268.9/169.9 for tolbutamide, 346/198 for omeprazole, 314/244 for efavirenz, 453.4/230.5 for repaglinide, and 501.4/198.2 for rolapitant (SCH619734). The MRM transitions for respective internal standards were dextromethorphan-d~3~ 275.2/215.2, tolbutamide-d~9~ at 277.9/169.6, omeprazole-d~3~ 349/197.9, efavirenz-d~4~ 317.9/247.9, repaglinide-ethyl-d~5~ 458.2/230.2, and ^13^C~3~-SCH619734 504/201. The validated ranges were 0.1 to 50 ng/mL for dextromethorphan, 100 to 50,000 ng/mL for tolbutamide, 2.0 to 1000 ng/mL for omeprazole, 10.0 to 5000 ng/mL for efavirenz, 0.02 to 10 ng/mL for repaglinide, and 2.0 to 2000 ng/mL for rolapitant.

### Pharmacokinetic evaluations {#Sec6}

The following pharmacokinetic parameters were calculated: maximum observed concentration (*C*~max~), time of observed maximum concentration (*T*~max~), area under the plasma concentration--time curve from time 0 to the time of the last quantifiable concentration (AUC~0--last~), area under the plasma concentration--time curve from time 0 extrapolated to infinity (AUC~0--inf~), and terminal elimination half-life (*t*~1/2~).

### Safety assessments {#Sec7}

Safety and tolerability were assessed by physical examinations, vital signs, laboratory safety tests, and reported AEs throughout the studies. The following safety parameters were recorded: clinical laboratory tests (clinical chemistry, hematology, and urinalysis), glucose monitoring for subjects receiving tolbutamide, 12-lead electrocardiograms (ECGs), vital signs (supine and orthostatic blood pressure, heart rate, and body temperature), physical examination, and concomitant medication monitoring.

### Pharmacokinetic and statistical analysis {#Sec8}

Individual plasma analyte concentration--time data were used to derive drug PK parameters using noncompartmental analyses performed with Phoenix^®^ WinNonlin^®^ 6.2 (Pharsight/Certara, Sunnyvale, CA, USA). SAS^®^ (SAS Institute, Cary, NC) software was used for the statistical analysis. To determine the effect of rolapitant on the PK of the investigational drugs, the log-transformed primary endpoints (AUC and *C*~max~) were analyzed using a repeated-measures ANOVA. Ninety percent confidence intervals (CIs) were constructed for the ratio of geometric least squares means.

Results {#Sec9}
=======

Patients {#Sec10}
--------

A total of 86 subjects were enrolled. Most of the subjects (97.7%) completed the studies. Two subjects in the tolbutamide plus omeprazole part withdrew early for reasons unrelated to study drugs (one subject had an anxiety attack and the other left due to a family emergency). The majority of subjects were male (73.6%) and not Hispanic or Latino (78.8%; Table [1](#Tab1){ref-type="table"}). Mean age ranged from 29.4 to 32.1 years and mean BMI from 24.1 to 26.1 kg/m^2^.Table 1Subject demographics and baseline characteristics in multipart rolapitant drug interaction studyParameterDextromethorphan (CYP2D6) *n* = 26Tolbutamide + omeprazole (CYP2C9/CYP2C19) *n* = 20Efavirenz (CYP2B6) *n* = 20Repaglinide (CYP2C8) *n* = 20Male, *n* (%)18 (69.2)13 (65.0)17 (85.0)15 (75.0)Mean age (SD), years30.4 (7.4)31.5 (5.8)32.1 (7.9)29.4 (6.7)Ethnicity, *n* (%) Not Hispanic or Latino21 (80.8)17 (85.0)12 (60.0)18 (90.0) Mean weight (SD), kg76.5 (10.5)79.3 (12.7)78.6 (9.6)73.8 (13.8) Mean BMI ± SD, kg/m^2^24.6 (2.9)26.1 (2.8)25.8 (3.0)24.1 (3.5)*BMI* body mass index, *SD* standard deviation

Interaction of dextromethorphan with rolapitant {#Sec11}
-----------------------------------------------

Median *T*~max~ for dextromethorphan alone was 2.0 h and for dextromethorphan and rolapitant was 3.0 h. The mean *t*~1/2~ for dextromethorphan alone was 7.5 h and for dextromethorphan and rolapitant was 9.6 h (Table [2](#Tab2){ref-type="table"}). Single-dose administration of rolapitant with dextromethorphan resulted in an increase in dextromethorphan exposure (increase by 2.3-fold for *C*~max~ and 2.6-fold for AUC~0--inf~) on day 7 and in the presence of rolapitant (increase by 2.8-fold for *C*~max~ and 3.3-fold for AUC~0--inf~) on day 14 (Table [3](#Tab3){ref-type="table"}). Similar increase in AUC~0--last~ was observed. Plasma concentration--time profiles for dextromethorphan demonstrated that dextromethorphan PK increased on day 7 when co-administered with rolapitant and increased on day 14 around peak metabolite concentration (Fig. [2](#Fig2){ref-type="fig"}a).Table 2Pharmacokinetic parameters of CYP probe substrates following single-dose oral administration of 180 mg rolapitant with or without CYP probe substrate to healthy subjectsTreatmentDayNumber*C*~max~ (ng/mL)*T*~max~ (h)AUC~0--last~ (ng h/mL)AUC~0--inf~ (ng h/mL)*t*~½~ (h)Mean (CV%)Median (range)Mean (CV%)Mean (CV%)Mean (CV%)Dextromethorphan (CYP2D6 substrate) DEX1263.11 (133)2.0 (1.0--4.0)32.3 (159)36.7 (146)^a^7.52 (45.2)^a^ DEX + ROL7265.36 (98.6)3.0 (1.5--6.0)62.1 (125)67.4 (120)^b^9.60 (40.5)^b^ DEX14265.72 (85.0)3.0 (1.5--4.0)70.1 (121)74.1 (118)10.2 (35.2)Tolbutamide (CYP2C9 substrate) TOL + OME12043,348 (16.6)3.5 (2.0--8.0)748,795 (55.8)801,801 (74.4)10.1 (70.5) TOL + OME+ ROL72041,849 (18.6)3.0 (1.5--4.0)685,748 (69.4)765,905 (101)10.4 (86.8) TOL + OME1418429,923 (19.7)4.0 (2.0--8.0)740,246 (66.5)817,760 (93.7)10.5 (82.5)Omeprazole (CYP2C19 substrate) TOL + OME120410 (62.2)1.9 (1.0--12.0)1188 (85.9)1151 (88.4)^c^1.63 (62.6)^c^ TOL + OME+ ROL720606 (61.3)2.0 (1.5--4.0)1461 (79.8)1538 (75.6)^d^2.18 (75.9)^d^ TOL + OME1418511 (49.5)2.0 (0.8--4.0)1339 (77.3)1429 (75.2)^c^1.57 (35.3)^c^Efavirenz (CYP2B6 substrate) EFV1202592 (22.2)3.0 (1.0--5.0)68,463 (21.9)102,617 (23.8)87.6 (44.3) EFV + ROL10202103 (19.1)3.5 (1.0--8.1)69,946 (20.6)113,011 (31.8)94.7 (42.1) EFV17202817 (19.2)3.5 (1.0--5.1)80,079 (21.3)135,904 (35.7)101 (41.5)Repaglinide (CYP2C8 substrate) REP1203.74 (38.5)0.5 (0.5--0.8)4.1 (33.7)4.4 (34.3)^c^3.01 (30.7)^c^ REP + ROL3204.13 (40.6)0.5 (0.5--1.0)4.6 (33.3)5.3 (31.1)^e^3.61 (54.7)^e^ REP10204.71 (26.5)0.5 (0.5--0.8)5.0 (30.5)5.6 (33.2)^f^3.76 (59.7)^f^*AUC* area under the plasma concentration--time curve, *C*~*max*~ maximum concentration, *CV* coefficient of variation, *DEX* dextromethorphan, *EFV* efavirenz, *OME* omeprazole, *REP* repaglinide, *ROL* rolapitant, *t*~*½*~ terminal elimination half-life, *T*~*max*~ time to maximum concentration, *TOL* tolbutamide^a^*N* = 24^b^*N* = 25^c^*N* = 16^d^*N* = 19^e^*N* = 13^f^*N* = 15Table 3Statistical analysis of effects of CYP interactionParameterGeometric least squares meanTreatment comparisonMean ratio90% confidence intervalDextromethorphanDextromethorphan + rolapitant5a: Effect of rolapitant on dextromethorphan PK---day 7 vs day 1*C* ~max~1.443.24Rolapitant + DEX vs DEX2.25(1.87, 2.70) AUC~(0--last)~9.2627.84Rolapitant + DEX vs DEX3.00(2.43, 3.72) AUC~(0--inf)~12.1231.20Rolapitant + DEX vs DEX2.58(2.13, 3.11)5a: Effect of rolapitant on dextromethorphan PK---day 14 vs day 1*C* ~max~1.4423.99Rolapitant + DEX vs DEX2.77(2.30, 3.33) AUC~(0--last)~9.2636.39Rolapitant + DEX vs DEX3.93(3.18, 4.86) AUC~(0--inf)~12.1240.38Rolapitant + DEX vs DEX3.33(2.76, 4.02)ParameterGeometric least squares meanTreatment comparisonMean ratio90% confidence intervalTolbutamideTolbutamide + rolapitant5b: Effect of rolapitant on tolbutamide PK---day 7 vs day 1*C* ~max~42,718.8841,100.97Rolapitant + TOL vs rolapitant0.96(0.91,1.02) AUC~(0--last)~676,029.20602,771.38Rolapitant + TOL vs rolapitant0.89(0.85, 0.94) AUC~(0--inf)~694,384.80624,546.67Rolapitant + TOL vs rolapitant0.90(0.85, 0.95)5b: Effect of rolapitant on tolbutamide PK---day 14 vs day 1*C* ~max~42,718.8841,727.74Rolapitant + TOL vs rolapitant0.98(0.92, 1.04) AUC~(0--last)~676,029.20640,009.92Rolapitant + TOL vs rolapitant0.95(0.90, 1.00) AUC~(0--inf)~694,384.80661,261.15Rolapitant + TOL vs rolapitant0.95(0.90, 1.01)ParameterGeometric least squares meanTreatment comparisonMean ratio90% confidence intervalOmeprazoleOmeprazole + rolapitant5c: Effect of rolapitant on omeprazole PK---day 7 vs day 1*C* ~max~337.20485.78Rolapitant + OME vs rolapitant1.44(1.12, 1.86) AUC~(0--last)~890.351088.53Rolapitant + OME vs rolapitant1.22(1.13, 1.32) AUC~(0--inf)~914.381127.10Rolapitant + OME vs rolapitant1.23(1.12, 1.36)5c: Effect of rolapitant on omeprazole PK---day 14 vs day 1*C* ~max~337.20460.56Rolapitant + OME vs rolapitant1.37(1.05, 1.78) AUC~(0--last)~890.351035.22Rolapitant + OME vs rolapitant1.16(1.07, 1.26) AUC~(0--inf)~914.391047.92Rolapitant + OME vs rolapitant1.15(1.03, 1.27)ParameterGeometric least squares meanTreatment comparisonMean ratio90% confidence intervalEfavirenzEfavirenz + rolapitant5d: Effect of rolapitant on efavirenz PK---day 10 vs day 1*C* ~max~2531.372067.62Rolapitant + EFV vs rolapitant0.82(0.74, 0.90) AUC~(0--last)~67,127.9368,601.89Rolapitant + EFV vs rolapitant1.02(0.96, 1.09) AUC~(0--inf)~99,812.77107,722.63Rolapitant + EFV vs rolapitant1.08(0.99, 1.17)5d: Effect of rolapitant on efavirenz PK---day 17 vs day 1*C* ~max~2531.372769.08Rolapitant + EFV vs rolapitant1.09(1.00, 1.20) AUC~(0--last)~67,127.9378,415.00Rolapitant + EFV vs rolapitant1.16(1.10, 1.24) AUC~(0--inf)~99,812.77127,843.75Rolapitant + EFV vs rolapitant1.28(1.18, 1.40)ParameterLeast squares meanTreatment comparisonMean ratio90% confidence intervalRepaglinideRepaglinide + rolapitant5e: Effect of rolapitant on repaglinide PK---day 3 vs day 1*C* ~max~3.533.76Rolapitant + REP vs rolapitant1.07(0.96, 1.19) AUC~(0--last)~3.924.35Rolapitant + REP vs rolapitant1.11(1.06, 1.16) AUC~(0--inf)~4.194.71Rolapitant + REP vs rolapitant1.12(1.07, 1.18)5e: Effect of rolapitant on repaglinide PK---day 10 vs day 1*C* ~max~3.534.56Rolapitant + REP vs rolapitant1.30(1.16, 1.44) AUC~(0--last)~3.924.80Rolapitant + REP vs rolapitant1.23(1.17, 1.28) AUC~(0--inf)~4.195.17Rolapitant + REP vs rolapitant1.23(1.18, 1.30)*C*~*max*~ maximum observed plasma concentration, *AUC(*~*0--120 h*~*)* area under the plasma concentration versus time curve from time 0 to 120 h, *AUC*~*(0--last)*~ area under the plasma concentration versus time curve from time 0 to time of final/last quantifiable sample, *AUC*~*(0--inf)*~ area under the plasma concentration versus time curve from time 0 extrapolated to infinity, *DEX* dextromethorphan, *EFV* efavirenz, *OME* omeprazole, *REP* repaglinide, *TOL* tolbutamideFig. 2Mean concentration--time profiles for (**a**) dextromethorphan, (**b**) tolbutamide, (**c**) omeprazole, (**d**) efavirenz, and (**e**) repaglinide with and without a single oral dose of rolapitant 180 mg administration

Statistical analysis demonstrated that rolapitant inhibited dextromethorphan metabolism resulting in higher exposure (*C*~max~ and AUC) of dextromethorphan following administration of rolapitant on day 7 and in the presence of M19 on day 14 (Table [3](#Tab3){ref-type="table"}). Geometric least square mean ratios for *C*~max~ and AUC~0--inf~ ranged between 2.2 and 3.3 for the comparisons of day 7/day 1 and day 14/day 1 parameter values, and the 90% CIs for the ratio of geometric least squares means were significantly greater than the 80 to 125% limits for *C*~max~ and AUC~0--inf~ (Table [3](#Tab3){ref-type="table"}).

Interaction of tolbutamide and omeprazole with rolapitant {#Sec12}
---------------------------------------------------------

Exposure (*C*~max~ and AUC) of tolbutamide and omeprazole following concomitant administration with rolapitant on day 7 and prolonged exposure to rolapitant on day 14 were similar to those on day 1, suggesting rolapitant does not impact the PK of tolbutamide and omeprazole. Plasma concentration--time profiles demonstrate there was no significant effect of rolapitant on tolbutamide and omeprazole PK (Fig. [2](#Fig2){ref-type="fig"}b, c). Statistical analysis confirmed that exposure to tolbutamide was not impacted by co-administration with 180 mg rolapitant. The 90% CI of geometric least square mean ratios for *C*~max~, AUC~0--last~, and AUC~0--inf~ of tolbutamide were contained within the 80 to 125% no effect limit (Table [3](#Tab3){ref-type="table"}). For omeprazole, statistical analysis demonstrated a minimal effect of rolapitant on the PK of omeprazole. Geometric least square mean ratios were 1.44 and 1.37 for *C*~max~ and 1.23 and 1.15 for AUC~0--inf~ for the comparisons of day 7/day 1 and day 14/day 1, respectively (Table [3](#Tab3){ref-type="table"}). However, these are unlikely to be clinically relevant.

Interaction of efavirenz with rolapitant {#Sec13}
----------------------------------------

The PK parameters for efavirenz following administration with or without rolapitant on days 10 and 17, respectively, were comparable to those obtained on day 1, indicating that rolapitant is not an inhibitor of efavirenz exposure. The mean plasma efavirenz concentration--time profile demonstrates there was no significant effect of rolapitant on efavirenz PK (Fig. [2](#Fig2){ref-type="fig"}d). The 90% CI of geometric least square mean ratios for AUC~0--last~ of efavirenz was contained within the 80 to 125% no effect limit (Table [3](#Tab3){ref-type="table"}). Minor excursions outside the no effect limit were observed for *C*~max~ and AUC~0--inf~ but are not expected to be clinically significant.

Interaction of repaglinide with rolapitant {#Sec14}
------------------------------------------

PK parameters of repaglinide on day 3 were similar to those on day 1. Co-administration of a single 180 mg dose of rolapitant with repaglinide resulted in a minimal increase in exposure of repaglinide on day 14 (Table [3](#Tab3){ref-type="table"}). Median *T*~max~ for repaglinide was unchanged for day 3 and day 10. The mean *t*~1/2~ for repaglinide alone on day 3 was 3.6 h, and repaglinide and rolapitant at day 10 was 3.8 h. Plasma concentration--time profile shows co-administration of rolapitant with repaglinide did not impact the PK of repaglinide (Fig. [2](#Fig2){ref-type="fig"}e). The 90% CIs for the ratio of geometric least squares means were contained within the 80 to 125% no effect limits for both *C*~max~ and AUC~0--inf~ for the day 3 and day 1 comparison but were slightly higher for day 10 and day 1 comparison. This is not expected to be clinically significant.

Safety {#Sec15}
------

In general, rolapitant was safe and well tolerated when co-administered with 30 mg dextromethorphan, 500 mg tolbutamide plus 40 mg omeprazole, 600 mg efavirenz, or 0.25 mg repaglinide. There were no serious treatment-emergent AEs (TEAEs) or deaths. The majority of TEAEs were mild and resolved spontaneously. In the dextromethorphan study, 4 out of 26 subjects experienced at least one TEAE that was judged to be related or probably related to study treatment. All TEAEs were of mild intensity and resolved by the end of study. During the tolbutamide and omeprazole study, 9 out of 26 subjects experienced at least one TEAE with most of the events being mild and resolved by the end of the study. One subject reported anxiety on day 14 leading to withdrawal from the study. During the efavirenz study, 15 out of 20 subjects experienced at least one TEAE, including dizziness, somnolence, and headaches. All TEAEs were treated and resolved during the study. In the repaglinide study, 9 out of 20 subjects experienced at least one TEAE, including migraines, upper respiratory infection, and headache. Additionally, no clinically significant changes in blood chemistry, vital signs, or ECGs occurred in the studies.

Discussion {#Sec16}
==========

CINV has a major deleterious effect on the functional capacity and quality of life of patients with cancer undergoing chemotherapy and has the potential to compromise adherence to life-prolonging treatment regimens \[[@CR17], [@CR18]\]. Administration of an NK-1 receptor antagonist, such as rolapitant, along with a 5-HT~3~-RAand dexamethasone has been incorporated into international antiemesis guidelines for control of CINV in patients receiving highly emetogenic chemotherapy and select patients receiving moderately emetogenic therapy \[[@CR4], [@CR19], [@CR20]\].

This is the first study to simultaneously assess the effects of oral rolapitant on the activity of multiple CYP enzymes in healthy subjects. Our findings indicate that IV rolapitant does not alter the activity of CYP2C9, CYP2C19, CYP2B6, or CYP2C8 to a clinically relevant extent, as evidenced by no effect or a weak effect of oral rolapitant on the *C*~max~ and AUC~0--inf~ of the substrates of these enzymes. Hence, oral rolapitant is not expected to alter appreciably the PK of concomitantly administered medications that are substrates of CYP2C9, CYP2C19, CYP2B6, or CYP2C8. However, oral rolapitant did alter the activity of CYP2D6 over a period of at least 7 days post oral rolapitant dose, as evidenced by a 3.3-fold increase in AUC~0--inf~ for dextromethorphan 7 days post rolapitant dose. Therefore, oral rolapitant is expected to increase systemic exposure of CYP2D6 substrates. For this reason, AE monitoring is required if oral rolapitant is given with CYP2D6 substrates that have a narrow therapeutic index if their concomitant use cannot be avoided. These findings are consistent with in vitro metabolism studies showing that rolapitant did not inhibit CYP3A4, CYP2C9, and CYP2C19 but did act as an inhibitor of CYP2D6 in vitro.

A single oral dose of 180 mg rolapitant was well tolerated when co-administered with all CYP probe substrates. Most TEAEs were of mild intensity, and there were no serious adverse events reported.

In conclusion, rolapitant was well tolerated when co-administered with CYP2D6, CYP2C9, CYP2C19, CYP2B6, or CYP2C8 probe substrates in this study. Inhibition of dextromethorphan by a single oral dose of 180 mg rolapitant is clinically significant and can last at least 7 days. No clinically significant interaction was observed between rolapitant and substrates of CYP2C9, CYP2C19, CYP2B6, or CYP2C8. CYP2D6 substrate drugs with a narrow therapeutic index may require monitoring for adverse reactions if given concomitantly with rolapitant.
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